Bold Therapeutics, Inc. Report issue

For profit Phase 1
Founded: Vancouver Canada (2018)

Organization Overview

First Clinical Trial
2020
NCT04421820
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Bold Therapeutics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (4)

bold-100 (1 trial)

fluorouracil (efudex) (1 trial)

leucovorin (1 trial)

oxaliplatin (eloxatin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cholangiocarcinoma (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 4